Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric ObesityGlobeNewsWire • 07/10/23
Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National AcademiesGlobeNewsWire • 07/06/23
Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine ProductsGlobeNewsWire • 07/03/23
Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLCGlobeNewsWire • 06/26/23
Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 06/15/23
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant CongressGlobeNewsWire • 06/07/23
Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacology MeetingGlobeNewsWire • 06/05/23
Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant CongressGlobeNewsWire • 05/31/23
Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International ConventionGlobeNewsWire • 05/30/23
Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingGlobeNewsWire • 05/25/23
Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative DiseasesGlobeNewsWire • 05/23/23
Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)GlobeNewsWire • 05/22/23
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare ConferenceGlobeNewsWire • 05/18/23
Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating DepressionGlobeNewsWire • 05/17/23
Tonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 05/08/23
Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney TransplantGlobeNewsWire • 05/04/23
A New Depression Drug Being Developed by Tonix May Side-Step Treatment-Limiting Effects of Nearly All Current Antidepressants in the USAccesswire • 04/27/23
Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 04/19/23
Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft SurvivalGlobeNewsWire • 04/17/23
Tonix Pharmaceuticals Presents Data from its Vaccine Development Program at the World Vaccine CongressGlobeNewsWire • 04/06/23
Tonix Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 04/05/23
Tonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in FibromyalgiaGlobeNewsWire • 03/30/23
